

The use of molecular adsorbent recirculating system and single-pass albumin dialysis as liver support: The experience of the Centro Médico Nacional 20 de Noviembre

Raul Sosa-Martinez¹, Karla Paola Perez-Lopez¹, Elizabeth Buganza-Torio², Mayra V. Ramos-Gomez¹

¹ Servicio de Gastroenterología, Centro Médico Nacional 20 de Noviembre

² Centro de Trasplante Hepático, Centro Médico Nacional 20 de Noviembre, Mexico

Introduction and Objectives: Acute on chronic liver failure (ACLF) describe a state of severe liver dysfunction. Extracorporeal liver support (ECLS) is a system that performs filtration and detoxification functions within an external device with the goal of reducing mortality or bypassing liver transplantation. The objective was to evaluate the effects of the molecular adsorbent recirculating system (MARS) and single-pass albumin dialysis (SPAD) in patients with acute-on-chronic in a tertiary Mexican hospital.

Materials and Patients: : Retrospectively, a search was performed in the internal electronic system with patients who required MARS or SPAD from 2016 to 2022.

Results: The results show a total of 18 patients with the diagnosis of acute on chronic liver failure who received treatment with MARS or SPAD. It was observed that 50% of the patients were women, with a mean age of 37.8 years.

The cause of the chronic liver disease was autoimmune hepatitis in 5 cases, 5 primary biliary cholangitis, 3 as cryptogenic cirrhosis, 2 viral, 1 hepatocarcinoma, 1 metabolism errors and 1 graft rejection. Within the support therapies used, it was found that 28% of the patients received MARS and 72% received SPAD, with a total of 49 sessions.

Clinically 77% of patients experienced improvement in hepatic encephalopathy and 66% improvement in renal function. At the end of the 90-day follow-up period, an overall survival rate of 52.94% was recorded.

Conclusions: These findings support the effectiveness of MARS and SPAD as viable ECLS options in patients with ACLF. The positive results in the improvement of encephalopathy and renal function, together with the survival rate, indicate the potential of these therapeutic approaches in the management of patients in this clinical setting. The sample size was small, which may affect the generalizability of the results.

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

None




Figure 1. Cumulative survival of patients treated with extracorporeal liver support.

<https://doi.org/10.1016/j.aohep.2024.101455>

Hepatitis C Virus NS5A and Core protein induce hepatic stellate cells activation promoting fibrosis-related gene regulation on hepatocytes.

Tania G. Heredia-Torres¹,
Sonia A. Lozano-Sepúlveda¹,
Ana R. Rincón-Sánchez²,
Ana M. Guadalupe Rivas-Estilla¹

¹ Departamento de Bioquímica y Medicina Molecular, Centro de Investigación e Innovación en Virología Médica Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

² IBMMTG, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México

Introduction and Objectives: Chronic HCV infection leads to the development of liver fibrosis mediated by intercellular communication between hepatocytes and hepatic stellate cells (HSCs). The diverse molecular pathways involved in the development of fibrosis in hepatocytes derived from HSC activation induced by viral proteins remain to be fully determined. Our aim is to determine differentially expressed genes associated with fibrotic processes in hepatocytes (Huh7) that express the HCV NS5A or Core protein during co-culture with HSC (LX2).

Materials and methods: Huh7 cells were transfected to express NS5A or Core proteins and co-cultured with HSC-LX2 cells. Viral protein expression and expression of TGFβ1, Col1, and αSMA was

determined to assess LX2 activation. A profile of 84 genes associated with fibrosis during co-cultivation was determined and analyzed.

Results: HSC-LX2 co-cultured with transfected Huh7 showed an 8.3, 6.7 and 4-fold increase in collagen1, TGF β 1 and timp1 expression respectively induced by NS5A and a 6.5, 1.8 and 6.2-fold increase respectively induced by Core, all these compared to HSC-LX2 co-cultured with untransfected Huh7. We detected 28 overexpressed genes in Huh7 (NS5A+) and 46 differentially expressed genes in Huh7 (Core +) in co-culture with HSC-LX2, compared to untransfected Huh7 in co-culture with HSC-LX2. Analysis of the expression profile showed that the TGF β 1, the ECM regulation, and growth factors pathways are the molecular mechanisms involved during the co-culture of Huh7 transfected with NS5A or Core with HSC-LX2.

Conclusions: HCV NS5A and Core proteins expression in Huh7 cells induces the HSC-LX2 activation, regulating the expression of diverse genes in hepatocytes that trigger different molecular mechanisms involved in the fibrosis development, this information provide the identification of possible anti-fibrotic targets drugs associated with HCV infection for further study.

Ethical statement

The protocol was registered and approved by the Ethics Committee.

Declaration of interests

None

Funding

The study was funded by the Department of Biochemistry and Molecular Medicine and CIIViM, School of Medicine, and by PAICYT 171-CS-2022 from Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León 64460, Mexico.

<https://doi.org/10.1016/j.aohep.2024.101456>

Hepatitis C virus-infected patients carriers of the TT (C*52T, rs14158) genotype of the LDL receptor and Apo3 present severe liver damage in West Mexico

Liliana Campos-Medina^{1,2}, Arturo Panduro^{1,2}, Karina Gonzalez-Aldaco^{1,2}, Saul Laguna-Meraz^{1,2}, Sonia Roman^{1,2}

¹ Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara, "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico

² Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico

Introduction and Objectives: The clinical course of hepatitis C virus infection (HCV) is modulated by environmental factors and genetic polymorphisms that interact with the virus, such as the low-density lipoprotein receptor (LDLR) and ligand Apolipoprotein E (ApoE); both are associated with lipid metabolism. However, the relationship of these genes with liver damage has not been jointly evaluated in Mexicans. The study aimed to identify a relationship between the LDLR polymorphism (C*52T, rs14158) and ApoE haplotype in anti-HCV positive patients with liver damage in a subpopulation of West Mexico.

Materials and Patients: This cross-sectional study included 152 naïve anti-HCV positive patients; 110 were viral load (VL) positive (+ve), and 42 were VL negative (-ve). A medical-nutritional evaluation was registered. LDLR and ApoE genotypes were assessed by allelic discrimination. Comparative statistical analysis was performed between VL+ve and VL-ve adjusted by genotype distribution and liver damage.

Written informed consent was obtained from the participants. The Institutional Review Board approved this study.

Results: The patients (85F/67M) were 49.8 $\pm$ 12 years of age with a BMI of 27.7 $\pm$ 5.4. VL +ve patients showed glucose homeostasis abnormalities (glucose >100 mg/dL, HOMA-IR >2.5); low levels of cholesterol, triglycerides, VLDL, and LDL, compared to VL-ve patients (p<0.001), as well as high-above-normal ALT, AST, GGT (p<0.001) and low platelets (p<0.001). A 61.1% (58/95) of the VL+ve patients had a high risk for fibrosis (FIB-4), and 35.7% (35/98) had severe fibrosis (APRI). A 10% (11/110) of the VL+ve patients were carriers of the TT LDLR/ApoE3 genotype in which 90% (10/11) had moderate/severe liver damage compared to the C allele carriers (CC, CT), whereas the VL-ve patients had 0% of the TT LDLR genotype (p=0.035) with a lower proportion of liver damage.

Conclusions: The presence of the TT LDLR/ApoE3 genotypes in VL +ve patients with hepatic function abnormalities suggests that it may be a valuable marker for risk of liver damage to avoid disease progression and to implement preventive strategies among the Mexican population.

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

None

<https://doi.org/10.1016/j.aohep.2024.101457>

LILLE-4 vs. LILLE-7 to predict short-term mortality in patients with severe alcoholic hepatitis

Claudia L. Dorantes-Nava¹, María F. Higuera-de la Tijera¹, Alfredo Servín-Caamaño², Gabriela Gutiérrez-Reyes³, Miguel Y. Carmona-Castillo¹, Sandra Teutli-Carrion¹, Ernesto J. Medina-Avalos¹, José L. Pérez-Hernández¹

¹ Department of Gastroenterology, Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico City

² Department of Internal Medicine, Hospital General de México "Dr. Eduardo Liceaga", Mexico City

³ Liver, Pancreas, and Motility Laboratory (HIPAM), Department of Experimental Medicine, Faculty of Medicine, Universidad Nacional Autonoma de Mexico (UNAM), Mexico City

Introduction and Objectives: Alcoholic hepatitis (AH) is an acute liver inflammation associated with excessive alcohol consumption. The pharmacological treatment for AH is corticosteroids. There is a study that has proposed calculating the Lille model on day 4 (Lille-4), which apparently has comparable accuracy to the Lille model calculated on day 7 (Lille-7). However, this finding has not been validated. Therefore our objective is to determine if Lille-4 is equivalent to Lille-7 in predicting 28-day mortality in patients with probable severe alcoholic hepatitis (AH) as defined by the 2016 consortium criteria sponsored by NIAAA.

Materials and Patients: Observational, prospective, ambidirectional, analytical cohort study conducted from January 2010 to April 2023. We collected clinical and biochemical variables upon admission, calculated Lille models, assessed response and 28-day mortality. Comparative analyses were performed based on survival versus